Protagonist Therapeutics stockholders approve 2026 Equity Incentive Plan and elect two directors
At its annual meeting, Protagonist Therapeutics stockholders approved the company's 2026 Equity Incentive Plan, which replaces the 2016 plan and adds 650,000 new shares for future awards. Stockholders also re-elected two Class I directors and approved the other proposals, including a non-binding say-on-pay vote and the ratification of Ernst & Young LLP as auditor.
Key points
- 2026 Equity Incentive Plan approved, adding 650,000 new shares plus returned shares from the 2016 plan
- Dinesh V. Patel, Ph.D., received 48,714,702 votes for and Lewis T. "Rusty" Williams, M.D., Ph.D., received 45,371,193 votes for
- Non-binding say-on-pay proposal approved with 53,412,559 votes for and 3,164,702 against
- Ernst & Young LLP ratified as independent registered public accounting firm for fiscal year ending December 31, 2026
The filing
Written by AI on Nov 8, 2026, 1:17 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 18, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.